AccScience Publishing / ITPS / Volume 2 / Issue 1 / DOI: 10.26689/itps.v2i1.550
Cite this article
34
Download
995
Views
Journal Browser
Volume | Year
Issue
Search
News and Announcements
View All
RESEARCH ARTICLE

Formulation Development and In Vitro Characterization of Zolmitriptan Controlled Release Drug Delivery Systems

Shambhavi Pandala1 Vasudha Bakshi1 Rajendra Kumar Jadi2
Show Less
1 Department of Pharmaceutics, Anurag Group of Institutions, School of Pharmacy, Venkatapur, Medchal, Hyderabad, Telangana, India.
2 Department of Pharmacy, University College of Technology, Osmania University, Hyderabad, Telangana, India.
INNOSC Theranostics and Pharmacological Sciences 2019, 2(1), 550 https://doi.org/10.26689/itps.v2i1.550
Submitted: 10 December 2018 | Accepted: 8 February 2019 | Published: 11 March 2019
© 2019 by the Authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution -Noncommercial 4.0 International License (CC-by the license) ( https://creativecommons.org/licenses/by-nc/4.0/ )
Abstract

Background: Zolmitriptan is an artificial tryptamine, employed for the acute cure of migraine attack with or exclusive 
of aura and cluster headaches. Objective: It is an attempt to develop the extended release (ER) of Zolmitriptan matrix (ZMT) tablets to treat migraine safely and effectively.
Methods: All formulations were prepared with natural polymers or gums like guar gum, xanthan gum, karaya gum through direct compression method using 6mm punch. 
Results: Powder blend of all formulations (F1 - F12) using different ratios of the above mentioned gums (5%, 10%, 15% 
and 20%) were characterized with pre-compression parameters (angle of repose, bulk density, tapped density, compressibility index, hausner ratio, compatibility studies) and post-compression parameters (weight variation, thickness, friability, hardness, assay, in vitro dissolution studies). F1 - F4 formulations were prepared with gum karaya and compared with remaining gums; gum karaya shows more retardance capacity. F9 - F12 (with guar gum) formulations were unable to produce the desired release, whereas F5 - F8 formulations containing with xanthan gum exhibited more retarding effect with increasing concentration of polymer.
Conclusion: All prepared formulations (F1 - F12) were characterized and F3 formulation was optimized (97.3% drug released in 8 hours). All prepared formulations (F1 - F12) showed good flow properties and release patterns. Hence, formulations of ZMT matrix tablets have a promising delivery system which will enhance bio-availability and achieve greater therapeutic efficacy.

Keywords
Zolmitriptan
controlled release
direct compression
bio-availability
therapeutic efficacy
References
[1]

Kohrs, J.N.; Liyanage, T.; Don, A.; Venkatesan, N.; Najarzadeh, A.; Puleo, A.D. Drug delivery systems and controlled release. In: Encyclopedia of Biomedical Engineering. United States: Elsevier; 2018. p316-329. Doi:10.1016/b978-0-12-801238-3.11037-2.

[2]

Davoodi, P.; Lee, L.Y.; Xu, Q.; Sunil, V.; Sun, Y.; Soh, S.; Wang, C.H. Drug delivery systems for programmed and ondemand release. Adv. Drug Deliv. Rev., 2018, 132, 104-138.

[3]

Hardenia, A.; Maheshwari, N.; Hardenia, S.S.; Dwivedi, S.K.; Maheshwari, R.; Tekade, R.K. Scientific rationale for designing controlled drug delivery systems. In: Basic Fundamentals of Drug Delivery. Cambridge, MA, USA: Academic Press; 2019. p. 1-28.

[4]

George, A.; Shah, P.A.; Shrivastav, P.S. Guar gum: Versatile natural polymer for drug delivery applications. Eur. Polym. J.,2018.https://doi.org/10.1016/j.eurpolymj.2018.10.042.

[5]

Chien, Y.W. Controlled and modulated release drug delivery systems. Encyclopedia Pharm. Technol., New York: Marcel Dekker; 1990. p280-313.

[6]

Ritschel, W.A.; Kearns, G.L. Absorption/transport mechanisms. In: Ritschel, W.A.; Kearns, G.L.; editors. Handbook of Basic Pharmacokinetics Including Clinical Applications. Washington, DC: American Pharmaceutical Association; 1999. p. 63.

[7]

Togaru, V.; Venisetty, R.K.; Bakshi, V.; Jadi, R.K. Formulation development and in vitro evaluation of propranolol hydrochloride extended release matrix tablets. Emergent Life Sci. Res., 2017, 3(1), 38-47.

[8]

Jadi, R.K.; Bomma, R.; Sellappan, V. Development of a new single unit dosage form of propranolol HCl extended release noneffervescent floating matrix tablets: In vitro and in vivo evaluation. J. Appl. Pharm. Sci., 2016, 6(5), 112-118.

[9]

Subedi, R.K.; Ryoo, J.P.; Moon, C.; Choi, H.K. Influence of formulation variables in transdermal drug delivery system containing zolmitriptan. Int. J. Pharm., 2011, 419(1-2), 209-214.

[10]

Tuchman, M.; Hee, A.; Emeribe, U.; Silberstein, S. Efficacy and tolerability of zolmitriptan oral tablet in the acute treatment of menstrual migraine. CNS Drugs, 2006, 20(12), 1019-1026.

[11]

Mauskop, A.; Farkkila, M.; Hering-Hanit, R.; Rapopot, A.; Warner, J. Zolmitriptan is effective for the treatment of persistent and recurrent migraine headache. Curr. Med. Res. Opin., 1999, 15(4), 282-289.

[12]

Dowson, A.J.; MacGregor, E.A.; Purdy, R.A.; Becker, W.J.; Green, J.; Levy, S.L. Zolmitriptan orally disintegrating tablet is effective in the acute treatment of migraine. Cephalalgia, 2002, 22(2), 101-106.

[13]

Tepper, S.J.; Donnan, G.A.; Dowson, A.J.; Bomhof, M.A.; Elkind, A.; Meloche, J.; Fletcher, P.E.; Millson, D.S. A long-term study to maximise migraine relief with zolmitriptan. Curr. Med. Res. Opin., 1999, 15(4), 254-271.

[14]

Lionetto, L.; Casolla, B.; Mastropietri, F.; D’Alonzo, L.; Negro, A.; Simmaco, M.; Martelletti, P. Pharmacokinetic evaluation of zolmitriptan for the treatment of migraines. Expert Opin. Drug Metab. Toxicol., 2012, 8(8), 1043-1050.

[15]

Panda, N.; Reddy, A.V.; Reddy, G.S.; Panda, K.C. Formulation design and in vitro evaluation of zolmitriptan immediate release tablets using primojel and AC-Di-Sol. J. Pharm. Sci. Res., 2015, 7(8), 545-553.

[16]

Jadi, R.K.; Tatikonda, A.; Reedy, P.R.; Venisetty, R.K. Design and characterization of pregabalin swellable core osmotic pumps. Int. J. Pharm. Res. Allied Sci., 2016, 5(3), 8-15.

[17]

Prasad, R.R.; Kumar, J.R.; Vasudha, B.; Chettupalli, A.K. Formulation development and evaluation of allopurinol solid dispersions by solvent evaporation technique. Int. J. Appl. Pharm., 2018, 10(4), 168-171.

[18]

Bayrak, Z.; Tas, C.; Tasdemir, U.; Erol, H.; Ozkan, C.K.; Savaser, A.; Ozkan, Y. Formulation of zolmitriptan sublingual tablets prepared by direct compression with different polymers: In vitro and in vivo evaluation. Eur. J. Pharm. Biopharm., 2011, 78(3), 499-505.

[19]

Mahmoud, A.A.; Salah, S. Fast relief from migraine attacks using fast-disintegrating sublingual zolmitriptan tablets. Drug Dev. Ind. Pharm., 2012, 38(6), 762-769.

[20]

Shiledar, R.R.; Tagalpallewar, A.A.; Kokare, C.R. Formulation and in vitro evaluation of xanthan gum-based bi-layered mucoadhesive buccal patches of zolmitriptan. Carbohydr. Polym., 2014, 101, 1234-1242.

[21]

Chen, G.L.; Hao, W.H. Factors affecting zero-order release kinetics of porous gelatine capsules. Drug Dev. Ind. Pharm., 1998, 24(6), 557-562.

[22]

Wagner, J.G. Interpretation of percent dissolved time plots derived from in vitro testing of conventional tablets and capsules. J. Pharm. Sci., 1969, 58(10), 1253-1257.

[23]

Higuchi, T. Mechanism of sustained action medication: Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J. Pharm. Sci., 1963, 52, 1145-1149.

[24]

Korsmeyer, R.W.; Gurny, R.; Doelker, E.; Buri, P.; Peppas, N.A. Mechanisms of solute release from porous hydrophilic polymers. Int. J. Pharm., 1983, 15, 25-35.

Conflict of interest
The authors declare no conflict of interest.
Share
Back to top
INNOSC Theranostics and Pharmacological Sciences, Electronic ISSN: 2705-0823 Published by AccScience Publishing